Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma

EGFR-mutated lung adenocarcinoma patients treated with gefitinib and osimertinib show a therapeutic benefit limited by the appearance of secondary mutations, such as EGFR(T790M) and EGFR(C797S). It is generally assumed that these secondary mutations render EGFR completely unresponsive to the inhibit...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Invest
Main Authors: Bousquet Mur, Emilie, Bernardo, Sara, Papon, Laura, Mancini, Maicol, Fabbrizio, Eric, Goussard, Marion, Ferrer, Irene, Giry, Anais, Quantin, Xavier, Pujol, Jean-Louis, Calvayrac, Olivier, Moll, Herwig P., Glasson, Yaël, Pirot, Nelly, Turtoi, Andrei, Cañamero, Marta, Wong, Kwok-Kin, Yarden, Yosef, Casanova, Emilio, Soria, Jean-Charles, Colinge, Jacques, Siebel, Christian W., Mazieres, Julien, Favre, Gilles, Paz-Ares, Luis, Maraver, Antonio
Format: Artigo
Language:Inglês
Published: American Society for Clinical Investigation 2019
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6994195/
https://ncbi.nlm.nih.gov/pubmed/31671073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI126896
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items